Evidence map›Paper›PMID 42209772›Full record

ArticleEndocrine2026

Factors associated with acquired hypothalamic obesity in children with hypothalamic tumors: a comparative single-center study.

Fulya Mete Kalayci, Deniz Özalp Kizilay, Eda Ataseven, Mehmet Kantar, Uluç Özkiziltan, Elif Bolat, Aslı Suner Karakülah, Damla Gökşen, Şükran Darcan, Samim Özen

Abstract readComparative Study
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fulya Mete KalayciDepartment of Pediatric Endocrinology and Diabetes, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0003-2853-0727
Deniz Özalp KizilayDepartment of Pediatric Endocrinology and Diabetes, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0003-4529-4404
Eda AtasevenDepartment of Pediatric Hematology and Oncology, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0003-3419-5814
Mehmet KantarDepartment of Pediatric Hematology and Oncology, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0002-1669-4321
Uluç ÖzkiziltanDepartment of Radiology, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0001-9270-976X
Elif BolatDepartment of Neurosurgery, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0003-1420-762X
Aslı Suner KarakülahDepartment of Biostatistics and Medical Informatics, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0002-6872-9901
Damla GökşenDepartment of Pediatric Endocrinology and Diabetes, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0001-6108-0591
Şükran DarcanDepartment of Pediatric Endocrinology and Diabetes, Ege University, İzmir, Türkiye, Turkey.ORCID 0000-0002-1330-6397
Samim ÖzenDepartment of Pediatric Endocrinology and Diabetes, Ege University, İzmir, Türkiye, Turkey. samim.ozen@ege.edu.tr.ORCID 0000-0001-7037-2713

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcquired hypothalamic obesity is a complex condition resulting from hypothalamic damage, often due to tumors. However, not all children with hypothalamic masses develop obesity; while hypothalamic involvement is a recognised factor, the impact of specific surgical approaches and concurrent endocrine deficits on diverse tumour cohorts requires further elucidation. To evaluate clinical, radiological, surgical, and endocrine factors associated with obesity in children with hypothalamic tumors.

methodsThis retrospective single-center study included 34 pediatric patients with hypothalamic tumors (median age at diagnosis: 6.0 years; IQR: 6) followed between 1999 and 2020. Patients with conditions or medications causing obesity were excluded. Data on tumor characteristics, treatment modalities, surgical approach, and endocrine abnormalities were collected. Obesity was defined as BMI > +2 SDS, and patients were grouped as obese and non-obese for comparative analysis.

resultsThe most frequent tumor types were optic glioma, pilocytic astrocytoma, and craniopharyngioma. Obesity developed in 15 patients (44.1%). The median time to obesity onset was 3.00 months (IQR: 12.50) after diagnosis, with no significant difference in total follow-up duration between obese and non-obese groups (3.00 vs 3.50 years, p=0.471). At diagnosis, the groups differed significantly regarding surgical history, particularly pterional craniotomy (p=0.048), and the presence of adrenal insufficiency (p=0.020) or hypogonadism (p=0.004). However, univariable logistic regression showed that surgical method was not significantly associated with obesity. Obesity was also significantly associated with insulin resistance (p=0.010) and dyslipidemia (p=0.019).

conclusionIn conclusion, hypothalamic obesity develops rapidly in children with hypothalamic tumors, often within the first few months following diagnosis. While surgical intervention-particularly via pterional craniotomy-showed a significant association with obesity in bivariate analysis, this association was not statistically significant in univariable logistic regression. The presence of obesity is closely linked to metabolic disturbances such as insulin resistance and dyslipidemia, as well as adrenal insufficiency and hypogonadism. These findings emphasize the necessity of early metabolic screening and personalized follow-up strategies immediately after diagnosis for this high-risk population.

Indexed as

Hypothalamic DiseasesHypothalamic NeoplasmsObesityPediatric ObesityAdolescentChildChild, PreschoolCraniopharyngiomaFemaleHumansMaleRetrospective StudiesChildrenCranial surgeryHypothalamic MassesObesitySetmelanotide

Identifiers

PMID42209772
PMCPMC13219077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.